As demand for structurally diverse mAbs grows, the purification process becomes more challenging. Study results show the efficacy of new technologies that address these hurdles, so customers are better prepared to meet growing demand and patient need:
- Detergent-based viral inactivation that is biodegradable and maintains the integrity of the protein of interest
- Enhanced chromatography ligand with higher dynamic binding capacity
- Additives in wash step successfully reduces aggregation
- Novel excipients reduce protein-protein interactions and improves stability
This content is sponsored by:
